Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT01208441
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01205685
- Locations
- 🇺🇸
Vanderbilt-Ingram Oncology Cool Springs, Franklin, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt One Hundre Oaks, Nashville, Tennessee, United States
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2018-09-12
- Target Recruit Count
- 63
- Registration Number
- NCT01194440
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 8
- Registration Number
- NCT01153672
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Mount Sinai Hospital, Canada
- Target Recruit Count
- 16
- Registration Number
- NCT01129622
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Heilongjiang University of Chinese Medicine
- Target Recruit Count
- 660
- Registration Number
- NCT01116167
- Locations
- 🇨🇳
Shanxi Hospital of Chinese Medicine, Taiyuan, Shanxi, China
🇨🇳SuqianMaternal and Child Health Hospital, Suqian, Jiangsu, China
🇨🇳Mudanjiang maternal and children hospital, Mudanjiang, Heilongjiang, China
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 28
- Registration Number
- NCT01105312
- Locations
- 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 112
- Registration Number
- NCT01077453
- Locations
- 🇺🇸
Arizona Cancer Center - Tucson, Tucson, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Arizona Health Sciences Center, Tucson, Arizona, United States
Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2010-02-22
- Lead Sponsor
- Korean Breast Cancer Study Group
- Target Recruit Count
- 495
- Registration Number
- NCT01072318
- Locations
- 🇰🇷
Department of Surgery, Asan medical center, Seoul, Korea, Republic of
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT01068704
- Locations
- 🇺🇸
Texas Oncology-Abilene, Abilene, Texas, United States
🇺🇸Texas Oncology-Beaumont, Beaumont, Texas, United States
🇺🇸Us Oncology Central Pharmacy, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.